367 related articles for article (PubMed ID: 24297864)
21. The treatment of relapsed and refractory multiple myeloma.
Richardson P; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Chauhan D; Munshi N; Anderson K
Hematology Am Soc Hematol Educ Program; 2007; ():317-23. PubMed ID: 18024646
[TBL] [Abstract][Full Text] [Related]
22. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
23. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
[TBL] [Abstract][Full Text] [Related]
24. Current treatment landscape for relapsed and/or refractory multiple myeloma.
Dimopoulos MA; Richardson PG; Moreau P; Anderson KC
Nat Rev Clin Oncol; 2015 Jan; 12(1):42-54. PubMed ID: 25421279
[TBL] [Abstract][Full Text] [Related]
25. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
26. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
[TBL] [Abstract][Full Text] [Related]
28. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.
Zhang J; Sattler M; Tonon G; Grabher C; Lababidi S; Zimmerhackl A; Raab MS; Vallet S; Zhou Y; Cartron MA; Hideshima T; Tai YT; Chauhan D; Anderson KC; Podar K
Cancer Res; 2009 Jun; 69(12):5082-90. PubMed ID: 19509231
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
30. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib.
Veschini L; Belloni D; Foglieni C; Cangi MG; Ferrarini M; Caligaris-Cappio F; Ferrero E
Blood; 2007 Mar; 109(6):2565-70. PubMed ID: 17110461
[TBL] [Abstract][Full Text] [Related]
32. Clinical update: novel targets in multiple myeloma.
Anderson KC
Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
[TBL] [Abstract][Full Text] [Related]
33. Constitutive expression of HIF-1alpha and HIF-2alpha in bone marrow stromal cells differentially promotes their proangiogenic properties.
Ben-Shoshan J; Schwartz S; Luboshits G; Maysel-Auslender S; Barzelay A; Polak-Charcon S; Tzahor E; Barshack I; Barak A; Levkovitch-Verbin H; Keren G; George J
Stem Cells; 2008 Oct; 26(10):2634-43. PubMed ID: 18687993
[TBL] [Abstract][Full Text] [Related]
34. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
[TBL] [Abstract][Full Text] [Related]
35. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Falchook GS; Wheler JJ; Naing A; Jackson EF; Janku F; Hong D; Ng CS; Tannir NM; Lawhorn KN; Huang M; Angelo LS; Vishwamitra D; Hess K; Howard AN; Parkhurst KL; Amin HM; Kurzrock R
Oncotarget; 2014 Nov; 5(21):10280-92. PubMed ID: 25373733
[TBL] [Abstract][Full Text] [Related]
36. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
[TBL] [Abstract][Full Text] [Related]
37. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Chauhan D; Tian Z; Nicholson B; Kumar KG; Zhou B; Carrasco R; McDermott JL; Leach CA; Fulcinniti M; Kodrasov MP; Weinstock J; Kingsbury WD; Hideshima T; Shah PK; Minvielle S; Altun M; Kessler BM; Orlowski R; Richardson P; Munshi N; Anderson KC
Cancer Cell; 2012 Sep; 22(3):345-58. PubMed ID: 22975377
[TBL] [Abstract][Full Text] [Related]
38. Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib.
Fernández de Larrea C; Martín-Antonio B; Cibeira MT; Navarro A; Tovar N; Díaz T; Rosiñol L; Monzó M; Urbano-Ispizua A; Bladé J
Leuk Res; 2013 Jun; 37(6):641-6. PubMed ID: 23395385
[TBL] [Abstract][Full Text] [Related]
39. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
40. Advances in treatment for relapses and refractory multiple myeloma.
Richards T; Weber D
Med Oncol; 2010 Jun; 27 Suppl 1():S25-42. PubMed ID: 20213220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
